CD19 CAR-γδT cell therapy for relapsed B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy—called CD19 CAR-γδT cells—for adults with B-cell lymphoma that has returned or not responded to standard treatments. The therapy uses your immune system's T cells, specially trained to find and attack cancer cells that carry the CD19 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a type of B-cell lymphoma that has come back or stopped responding to treatment.
- Your lymphoma cells must test positive for a protein called CD19.
- You must have at least one tumor that can be measured on a scan (1.5 cm or larger).
- Your organs (heart, kidneys, liver) must be working well enough to handle the therapy.
- You cannot have active brain involvement, other uncontrolled cancers, or serious infections like HIV or hepatitis.
- You must agree to use effective birth control during treatment and for one year after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (CAR-γδ T cells) that targets a protein called CD19 found on leukemia cells. It is for people with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets CD19 on leukemia cells. It is for people with B-cell acute lymphoblastic leukemia that has not responded to treatment or has come back.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Hear when a new Recurrent/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.